Abstract 1276P
Background
EXcellenT (NCT05306652) is a prospective randomized trial on PA in oncogene-addicted advanced NSCLC pts in active treatment with TKIs. These pts are often young, keen to regain their pre-disease QoL and have prolonged survival. Depression may hamper compliance and response to treatment and delay social life recovery. This trial evaluates if tailored PA have an impact on QoL, metabolic and immune status.
Methods
Pts are randomized in an interventional arm of a personalized supervised PA prescription (arm A) or a counseling on home-based exercise (arm B). Depression is assessed by Beck’s Depression Inventory (BDI) questionnaires administered at week (wk) 0 and 12. Blood samples are collected at baseline, wk 4 and 12 for metabolic and immune status evaluation. Fatty acid (FA) composition is carried out using gas liquid chromography with flame ionization detection and liquid chromatography-mass spectrometry; immune cell composition through flow cytometry.
Results
Preliminary data on personalized PA influence on depression are available for 22 pts enrolled, FA analysis and immune cells count for 4 and 3 pts, respectively. Pts characteristics are: median age 53 yo, 53% female, 80% ECOG PS 0, 52% pre-diagnosis leisure-time PA; ALK+ 53%, EGFR+ 31%, BRAF+ 13%, RET+ 3%, ROS1+ 16%. In arm A depressive symptoms improved at wk 12 vs wk 0 (BDI mean difference: 6 points [IQR 4-9], p=0.0039). Only a trend to improvement was found in arm B (p=0.1270). The extent of improvement between the 2 time points was more sustained in arm A than arm B (p=0.0237). Plasma analysis showed a significant increase in Mono-Unsaturated Fatty Acids (p=0.0329) whereas FACS analysis highlighted reduction in circulating CD34+ hematopoietic stem cell (p=0.0112, ANOVA, Tukey’s multiple comparisons) and parallel increase in mature CD66b+CD10+ neutrophils.
Conclusions
The preliminary analysis of our trial confirms that a tailored PA program can significantly improve depression state, increase mature immune cell precursors and enhance metabolic state. A personalized PA program should be integrated to standard oral therapies to enhance NSCLC pts well-being and not only treat their disease.
Clinical trial identification
NCT05306652.
Editorial acknowledgement
Legal entity responsible for the study
AUSL della Romagna.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1324P - Durvalumab in treatment-naive, stage IV non-small cell lung cancer (NSCLC) patients (pts), with ECOG performance status (PS) 2-3 and high PD-L1 tumour expression: Results of IFCT-1802 SAVIMMUNE phase II trial
Presenter: Valerie Gounant
Session: Poster session 05
1325P - TRIDENT: Machine learning (ML) multimodal signatures to identify patients that would benefit most from tremelimumab (T) addition to durvalumab (D) + chemotherapy (CT) with data from the POSEIDON trial
Presenter: Ferdinandos Skoulidis
Session: Poster session 05
1326P - Clinical and genomic characteristics of advanced non-small cell lung cancer (aNSCLC) patients (pts) with long-term response to first-line (1L) immunotherapy: A real-world study
Presenter: Sameh Daher
Session: Poster session 05
1327P - Lung immune prognostic index (LIPI) as a guide for addition of chemotherapy in immunotherapy in elderly patients (Pts) with non-small cell lung cancer (NSCLC): NEJ057
Presenter: OSAMU HONJO
Session: Poster session 05
1328P - Dynamic blood immune-inflammatory and radiomic profiling to decode distinct patterns of acquired resistance to immunotherapy in NSCLC patients
Presenter: Giulia Mazzaschi
Session: Poster session 05
1330P - Phase II study of pembrolizumab (pemb) plus plinabulin (plin) and docetaxel (doc) for patients (pts) with metastatic NSCLC after failure on first-line immune checkpoint inhibitor alone or combination therapy: Initial efficacy and safety results on Immune Re-sensitization
Presenter: Yan Xu
Session: Poster session 05
1331P - Efficacy, innovativeness, clinical trials, endpoints, and price of drugs with FDA approval for non-small cell lung cancer (NSCLC)
Presenter: Christoph Michaeli
Session: Poster session 05
1332P - Effects of immune checkpoint inhibitors for EGFR-wild/ALK-negative NSCLC patients with untreated brain metastases
Presenter: Toshihiko Iuchi
Session: Poster session 05
1333P - Prognostic value of circulating nucleosomes during treatment with or without immunotherapy in non-small lung cancer (NSCLC): Results from the NUCLEO-lung study
Presenter: Léa Payen
Session: Poster session 05